
## CLAIMS

1. A neurotrophin production/secretion promoting agent which comprises an azole derivative of the formula :



- wherein R1 represents a halogen atom, a heterocyclic group 5 which may optionally be substituted, a hydroxy group which may optionally be substituted, a thiol group which may optionally be substituted, or an amino group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which 10 may optionally be substituted, a hydroxy group which may optionally be substituted, or a carboxyl group which may optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; X represents oxygen atom, sulfur atom, or nitrogen atom which 15 may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof.
- A neurotrophin production/secretion promoting agent
   which comprises a prodrug of an azole derivative or a salt thereof as defined in Claim 1.
  - 3. An agent according to Claim 1, wherein R<sup>1</sup> is a nitrogen-containing heterocyclic group which may optionally be substituted.

25

- 4. An agent according to Claim 1, wherein R<sup>1</sup> is an aromatic heterocyclic group which may optionally be substituted.
- 30 5. An agent according to Claim 1, wherein R<sup>1</sup> is a nitrogen-containing 5-membered aromatic heterocyclic group which may optionally be substituted.

- 6. An agent according to Claim 1, wherein  $R^1$  is an imidazolyl group which may optionally be substituted.
- 7. An agent according to Claim 1, wherein A is a heterocyclic group which may optionally be substituted, or a hydroxy group which may optionally be substituted.
- 8. An agent according to Claim 1, wherein A is an aryloxy group which may optionally be substituted.
  - 9. An agent according to Claim 1, wherein A is a phenoxy group substituted with an alkyl group which may optionally be substituted.

10. An agent according to Claim 1, wherein B is a phenyl group which may optionally be substituted.


15

30

- 11. An agent according to Claim 1, wherein Y is a divalent20 aliphatic hydrocarbon group.
  - 12. An agent according to Claim 1, wherein X is -O-.
- 13. An agent according to Claim 1, wherein X is -S-. 25
  - 14. An agent according to Claim 1, wherein X is -NR<sup>4</sup>-wherein R<sup>4</sup> represents a hydrogen atom, a hydrocarbon group which may optionally be substituted, an acyl group which may optionally be substituted, or a heterocyclic group which may optionally be substituted.
  - 15. An agent according to Claim 1, wherein the azole derivative is 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolepropanol, 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolebutanol, 4-(4-chlorophenyl)-5-[3-(1-imidazolyl)propyl]-2-(2-methyl-1-imidazolyl)propyl]

imidazolyl)oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1imidazolyl)-5-oxazolepentanol, 4-(4-chlorophenyl)-5-[4-(1-imidazolyl)butyl]-2-(2-methyl-1-imidazolyl)oxazole, 3-[3-[4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5oxazolyl]propyl]-1-methyl-2,4-imidazolidinedione, 4-(4chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2methyl-1-imidazolyl)oxazole, 4-(4-chlorophenyl)-5-[3-(3-methoxyphenoxy)propyl]-2-(2-methyl-1imidazolyl)oxazole, 4-(4-chlorophenyl)-5-[3-(4methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole, 10 or 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole.

- 16. An agent according to Claim 1 which is a 15 prophylactic/therapeutic agent for neuropathy.
  - An agent according to Claim 1 which is a prophylactic/therapeutic agent for peripheral neuropathy.
- 20 A thiazole derivative of the formula :



30

wherein R1a represents a heterocyclic group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group which may 25 optionally be substituted, or a carboxyl group which may optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof.

19. A prodrug of a thiazole derivative or a salt thereof

as defined in Claim 18.

15

25

- 20. A compound according to Claim 18, wherein R<sup>1a</sup> is a nitrogen-containing 5-membered aromatic heterocyclic group which may optionally be substituted.
- 21. A compound according to Claim 18, wherein R<sup>1a</sup> is an imidazolyl group which may optionally be substituted.
- 10 22. A compound according to Claim 18, wherein A is an aryloxy group which may optionally be substituted.
  - 23. A compound according to Claim 18, wherein B is a phenyl group which may optionally be substituted.

24. A compound according to Claim 18, wherein Y is a divalent aliphatic hydrocarbon group.

- 25. A pharmaceutical composition which comprises a20 thiazole derivative or a salt thereof as defined in Claim18.
  - 26. A composition according to Claim 25 which is a neurotrophin production/secretion promoting agent.
  - 27. A composition according to Claim 25 which is a prophylactic/therapeutic agent for neuropathy.
- 28. A composition according to Claim 25 which is a 30 prophylactic/therapeutic agent for peripheral neuropathy.
  - 29. An oxazole derivative of the formula :

$$R^{1}$$
  $O$   $Y$   $A^{b}$ 

10

wherein R<sup>1</sup> represents a halogen atom, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, a thiol group which may 5 optionally be substituted, or an amino group which may optionally be substituted; Ab represents an aryloxy group which is substituted by an alkyl group and may further be substituted: B represents an aromatic group which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof.

- A compound according to Claim 29, wherein Ab is an aryloxy group which is substituted by an alkyl group.
- A prodrug of an oxazole derivative or a salt thereof 15 as defined in Claim 29.
- 32. A compound according to Claim 29, wherein R1 is a nitrogen-containing 5-membered aromatic heterocyclic group which may optionally be substituted. 20
  - 33. A compound according to Claim 29, wherein R1 is an imidazolyl group which may optionally be substituted.
- A compound according to Claim 33, wherein R1 is an 25 imidazolyl group which may optionally be substituted by a  $C_{1-10}$  alkyl.
- A compound according to Claim 29, wherein B is a phenyl group which may optionally be substituted. 30
  - A compound according to Claim 35, wherein B is a phenyl

group which may optionally be substituted by halogens.

- 37. A compound according to Claim 29, wherein Y is a divalent aliphatic hydrocarbon group.
- 38. A compound according to Claim 37, wherein Y is a divalent  $C_{1-4}$  aliphatic hydrocarbon group.

5


15

35

- 39. A pharmaceutical composition which comprises an 10 oxazole derivative or a salt thereof as defined in Claim 29.
  - 40. A composition according to Claim 39 which is a neurotrophin production/secretion promoting agent.
- 41. A composition according to Claim 39 which is a prophylactic/therapeutic agent for neuropathy.
- 42. A composition according to Claim 39 which is a20 prophylactic/therapeutic agent for peripheral neuropathy.
  - 43. 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole or a salt thereof.
- 25 44. A crystal of 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole or a salt thereof.
- 45. 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-30 (3-methylphenoxy)propyl]oxazole or a salt thereof.
  - 46. A crystal of 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(3-methylphenoxy)propyl]oxazole or a salt thereof.
  - 47. 5-[3-(4-Chloro-2-methylphenoxy)propyl]-4-(4-

chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole or a salt thereof.

- 48. A crystal of 5-[3-(4-chloro-2
  methylphenoxy)propyl]-4-(4-chlorophenyl)-2-(2-methyl-1imidazolyl)oxazole or a salt thereof.
- 49. A method for promoting neurotrophin production/secretion in a mammal in need thereof, which comprises administering to said mammal an effective amount of an azole derivative of the formula:



15


wherein R¹ represents a halogen atom, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, or an amino group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, or a carboxyl group which may optionally be substituted, or a carboxyl group which may optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; X represents oxygen atom, sulfur atom, or nitrogen atom which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof.

50. A method for promoting neurotrophin production/secretion in a mammal in need thereof, which comprises administering to said mammal an effective amount of a thiazole derivative of the formula:

$$R^{1a}$$
  $S$   $Y$ — $A$ 

wherein R<sup>1a</sup> represents a heterocyclic group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, or a carboxyl group which may optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof.

51. A method for promoting neurotrophin production/secretion in a mammal in need thereof, which comprises administering to said mammal an effective amount of an oxazole derivative of the formula:



10

15

20

25

wherein R¹ represents a halogen atom, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, a thiol group which may optionally be substituted, or an amino group which may optionally be substituted; Ab represents an aryloxy group which is substituted by an alkyl group and may further be substituted; B represents an aromatic group which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof.


52. A method for preventing or treating neuropathy in a

mammal in need thereof, which comprises administering to said mammal an effective amount of a thiazole derivative of the formula:

$$R^{1a}$$
  $S$   $Y$   $A$ 

wherein R<sup>1a</sup> represents a heterocyclic group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, or a carboxyl group which may optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof.


15 53. A method for preventing or treating neuropathy in a mammal in need thereof, which comprises administering to said mammal an effective amount of an oxazole derivative of the formula:



wherein R<sup>1</sup> represents a halogen atom, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, a thiol group which may optionally be substituted, or an amino group which may optionally be substituted; A<sup>b</sup> represents an aryloxy group which is substituted by an alkyl group and may further be substituted; B represents an aromatic group which may optionally be substituted; and Y represents a divalent

hydrocarbon group or heterocyclic group, or a salt thereof.

54. Use of an azole derivative of the formula :



wherein R¹ represents a halogen atom, a heterocyclic group which may optionally be substituted, a thiol group which may optionally be substituted, or an amino group which may optionally be substituted; A represents an acyl group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, or a carboxyl group which may optionally be substituted, or a carboxyl group which may optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; X represents oxygen atom, sulfur atom, or nitrogen atom which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof, for the manufacture of a neurotrophin production/secretion promoting agent.


20

25

10

15

55. Use of a thiazole derivative of the formula :




wherein R<sup>1a</sup> represents a heterocyclic group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, or a carboxyl group which may

optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof,


for the manufacture of a neurotrophin production/secretion promoting agent.

56. Use of an oxazole derivative of the formula:



wherein R¹ represents a halogen atom, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, a thiol group which may optionally be substituted, or an amino group which may optionally be substituted; Ab represents an aryloxy group which is substituted by an alkyl group and may further be substituted; B represents an aromatic group which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof, for the manufacture of a neurotrophin production/secretion promoting agent.


57. Use of a thiazole derivative of the formula :



wherein R<sup>1a</sup> represents a heterocyclic group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, or a carboxyl group which may optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof,

for the manufacture of a pharmaceutical preparation for preventing or treating neuropathy.

## 58. Use of an oxazole derivative of the formula:



wherein R<sup>1</sup> represents a halogen atom, a heterocyclic group

15

which may optionally be substituted, a hydroxy group which may optionally be substituted, a thiol group which may optionally be substituted, or an amino group which may optionally be substituted; A<sup>b</sup> represents an aryloxy group which is substituted by an alkyl group and may further be substituted; B represents an aromatic group which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof, for the manufacture of a pharmaceutical preparation for

20 for the manufacture of a pharmaceutical preparation for preventing or treating neuropathy.